HDAC9 and cancer: These data show that only one compound, the multitargeted HDAC inhibitor panobinostat (IC50 = 0.355 ± 0.268 μM; SI = 0.92 ± 0.57), exhibited sub-μM potency in every cancer cell line among 11 cancer cell lines tested (Supplementary Figure 9B).